H.C. Wainwright analyst Andrew Fein downgraded Fulcrum Therapeutics to Neutral from Buy with a price target of $6, down from $20. The FDA response letter on FTX-6058 brings risk of hematological malignancies to the forefront, the analyst tells investors in a research note. The firm expects the stock to continue to trade close to its 52-week low until resolution of the clinical hold. It downgrades the shares pending further clarity on a development pathway forward.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FULC:
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics downgraded to Neutral from Outperform at Credit Suisse
- Oppenheimer ‘not writing off’ Fulcrum Therapeutics’ 6058 ‘just yet’
- Fulcrum Therapeutics downgraded to Hold from Buy at Stifel
- Fulcrum Therapeutics CMO Santiago Arroyo departs, Iain Fraser named interim